Skip to main content
SpringerLink
Log in

Misunderstanding or error?

the UGDP report after four years

  • Published:
Acta diabetologia latina Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. American Diabetes Association: Labeling of Oral Hypoglycemic Drugs — Diabetes21, 833, 1972.

    Google Scholar 

  2. Association des Diabétologues de Langue Française: À propos de l’UGDP — Diabète (Le Raincy)19, 120, 1971.

    Google Scholar 

  3. Australian Drug Evaluation Committee: Oral Hypoglycaemic Agents in the Treatment of Diabetes Mellitus — New Ethicals 9, 1971.

  4. Balodimos M. C., Gleason R. E., Bradley R. F., Marble A.: Long-Term Tolbutamide Therapy in Diabetes: a Controlled Study of the Frequency of Cardiovascular Disease and Other Findings — In:Butterfield W. J. H., van Westering W. (Eds): Tolbutamide… after Ten Years. Excerpta Medica Foundation, Amsterdam, 1967; p. 270.

    Google Scholar 

  5. Balodimos M. C., Marble A., Rippey J. H., Legg M. A., Kuwabara T., Gleason R. E.: Pathological Findings after Long-Term Sulphonylurea Therapy — Diabetes17, 503, 1968.

    PubMed  CAS  Google Scholar 

  6. Bernheim R.: Les antidiabétiques oraux jouent-ils un rôle dans la mortalité cardiovasculaire du diabète? À propos du rapport de l’U.G.D.P. et des controverses qu’il a suscitées. Table ronde — Presse méd.79, 2437, 1971.

    Google Scholar 

  7. Bloodworth J. M. B. Jr., Hamwi G. J.: Histopathologic Lesions Associated with Sulfonylurea Administration — Diabetes10, 90, 1961.

    Google Scholar 

  8. Blumenthal H. T., Morris A., Goldenberg S.: A Study of Lesions of the Intramural Coronary Artery Branches in Diabetes Mellitus — Arch. Path.70, 27, 1960.

    Google Scholar 

  9. Boston Collaborative Drug Surveillance Program: Coffee Drinking and Acute Myocardial Infarction — Lancet2, 1278, 1972.

    Google Scholar 

  10. Boyle D., Bhatia S. K., Hadden D. R., Montgomery D. A. D., Weaver J. A.: Ischaemic Heart-Disease in Diabetics. A Prospective Study — Lancet1, 338, 1972.

    Article  PubMed  CAS  Google Scholar 

  11. Bradley R. F., Forsham P. H., Dolger H., Ashmore J. D., Seltzer H., Beaser S. B., Challoner D. R., Camerini-Dávalos R. A., Dobson H. L., Delauter D. E., Felts P. W., Feldman R., Fulton R. I., Friedman G. J., Gates E. W., Hare R. L., Haunz E. A., Jacobson W. E., Kent G., Krosnick A., Marble A., Miller L., Moss J. M., McDonald G. W., Oppenheimer H. J., O’Sullivan J. B., Peebles-Meyers M., Schumacher O. P., Shuman C., Silver A. A., Sisk C. W., Soeldner J. S., Stephens J. W., Welsh G.: Treatment of Diabetes. Statement from a Newly Formed Committee — Northw. Med. (Seattle)70, 8, 1971.

    Google Scholar 

  12. Canaani Z.: Some Evidence for the Innocence of Long-Term Tolbutamide Treatment on the Frequency of Cardiovascular Disease — In:Shafrir E. (Ed.): Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med. Sci.8, 699, 1972.

    Google Scholar 

  13. Canadian Diabetic Association: Statement Concerning Tolbutamide — Rx Bulletin, May 1971; p. 65.

  14. Carlson L. A., Böttiger L. E.: Ischaemic Heart-Disease in Relation to Fasting Values of Plasma Triglycerides and Cholesterol. Stockholm Prospective Study — Lancet1, 865, 1972.

    Article  PubMed  CAS  Google Scholar 

  15. Carlström S., Persson G., Scherstén B.: A Critical Evaluation of a Diabetes Survey: Ten Years Afterwards — 8th Meeting of the European Study Group for Diabetes Epidemiology, Milan, May 3–4, 1973.

  16. Committee on Safety of Drugs: Report for 1969 and 1970 — Her Majesty’s Stationery Office, London, 1971.

    Google Scholar 

  17. Constam G. R.: Is the Use of Sulphonylurea Derivatives in the Treatment of Diabetes Mellitus Dangerous? — Diabetologia7, 237, 1971.

    Article  PubMed  CAS  Google Scholar 

  18. Cornfield J.: The University Group Diabetes Program. A Further Statistical Analysis of the Mortality Findings — J. Amer. med. Ass.217, 1676, 1971.

    Article  CAS  Google Scholar 

  19. Deutsche Diabetes-Gesellschaft: Kein Risiko bei Tolbutamid-Therapie des Diabetes — Dtsch. Arzt 2204, 1970.

  20. Deutsche Diabetes-Gesellschaft: Langzeitbehandlung der Zuckerkrankheit mit Tabletten — Dtsch. Arzt 640, 1971.

  21. Doyle J. T., Dawber T. R., Kannel W. B., Kinch S. H., Kahn H. A.: The Relationship of Cigarette Smoking to Coronary Heart Disease. The Second Report of the Combined Experience of the Albany (N. Y.) and Framingham (Mass.) Studies — J. Amer. med. Ass.190, 886, 1964.

    CAS  Google Scholar 

  22. Drury M. I., Timoney F. J.: Oral Hypoglycaemic Agents and Cardiovascular Deaths in Diabetes — Acta diabet. lat.9, 645, 1972.

    Article  CAS  Google Scholar 

  23. Editorial: Are Antidiabetic Drugs Dangerous? — Brit. med. J.4, 444, 1970.

  24. Editorial: Status of Problem of Usage of Tolbutamide. Preliminary Statements — Diabetes19, 467, 1970.

  25. Editorial: The Tolbutamide Evidence — Lancet1, 171, 1971.

  26. Editorial: Use of Tolbutamide and Other Sulphonylureas in Diabetes Mellitus, in the Light of the University Group Diabetes Program (UGDP) Report — Med. Proc.17, 265, 1971.

  27. Edwards C. C.: Oral Hypoglycemic Agents. Report of the Food and Drug Administration — Diabetes19 (Suppl. 2), viii, 1970.

    Google Scholar 

  28. Fajans S. S.: Review of University Group Diabetes Program (UGDP) — Evian Diabetes Symposium, September 3–4, 1971.

  29. Fearnley G. R.: Pharmacological Fibrinolysis in Occlusive Vascular Disease, and its Relation to Diabetes Mellitus — Postgrad. med. J.45, 52, 1969.

    PubMed  CAS  Google Scholar 

  30. Feinstein A. R.: Clinical Biostatistics. VIII. An Analytic Appraisal of the University Group Diabetes Program (UGDP) Study — Clin. Pharmacol. Ther.12, 167, 1971.

    PubMed  CAS  Google Scholar 

  31. Felig J.: Discussion Remark. Panel Discussion on: Oral Substitutes for Insulin: Modern Appraisal of Their Action and Indications — In:Shafrir E. (Ed.): Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med. Sci8, 708, 1972.

    Google Scholar 

  32. Fidel J.: Vascular Complications in Diabetic Patients in the Jerusalem Area Treated by Diet, Tolbutamide and Insulin — In:Shafrir E. (Ed.): Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med.8, 705, 1972.

    Google Scholar 

  33. Food and Drug Administration: Final Labeling of Oral Hypoglycemic Drugs — FDA Drug Bull., Maggio 1970.

    Google Scholar 

  34. Garcia M. J., Gordon T., McNamara P. M., Kannel W. B.: Morbidity and Mortality in Diabetics in a General Population. Sixteen-Year Follow-up Experience in the Framingham Study — Diabetes19 (Suppl. 1), 375, 1970.

    Google Scholar 

  35. Gelin J., Elgrishi I., Ducimetière P., Richard J. L.: L’électrocardiogramme dans une population à haut risque — In: Enquête épidémiologique sur les facteurs de l’athérosclérose. (Premiers résultats 1963–1964). Bull. Inst. nat. Santé et Rech. méd.22, 279, 1967.

    CAS  Google Scholar 

  36. Goldner M. G.: Introductory Remarks. Panel Discussion on: Oral Substitutes for Insulin: Modern Appraisal of Their Action and Indications — In:Shafrir E. (Ed.): Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med. Sci.8, 677, 1972.

    Google Scholar 

  37. Goldner M. G., Knatterud G. L., Prout T. E.: Effects of Hypoglycemic Agents on Vascular Complications in Patients with Adult-Onset Diabetes. III. Clinical Implications of UGDP Results — J. Amer. med. Ass.218, 1400, 1971.

    Article  CAS  Google Scholar 

  38. Gordon T., Kannel W. B.: Predisposition to Atherosclerosis in the Head, Heart, and Legs. The Framingham Study — J. Amer. med. Ass.221, 661, 1972.

    Article  CAS  Google Scholar 

  39. Hadden D. R., Montgomery D. A. D., Weaver J. A.: Myocardial Infarction in Maturity-Onset Diabetics. A Retrospective Study — Lancet,1, 335, 1972.

    Article  PubMed  CAS  Google Scholar 

  40. Jarrett R. J.: Diabetes, Hyperglycaemia and Arterial Disease — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 7, 1971.

    Google Scholar 

  41. Kappert A.: Tobacco and Diabetic Angiopathy — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 429, 1971.

    Google Scholar 

  42. Keen H.: Discussion Remark — 30th Annual Meeting of the Amer. Diabetes Ass., St. Louis, 1970.

    Google Scholar 

  43. Keen H.: Minimal Diabetes and Arterial Disease: Prevalence and the Effect of Treatment — In:Camerini-Dávalos R. A., Cole H. S. (Eds): Early Diabetes. Academic Press, New York-London, 1970; p. 437.

    Google Scholar 

  44. Keen H.: Factors Influencing the Progress of Atherosclerosis in the Diabetic — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 444, 1971.

    Google Scholar 

  45. Keen H., Jarrett R. J.: The Effect of Carbohydrate Tolerance on Plasma Lipids and Atherosclerosis in Man — In:Jones R. J. (Ed.): Atherosclerosis. Proceedings of the Second International Symposium on Atherosclerosis, Chicago 1969. Springer-Verlag, Berlin-Heidelberg-New York, 1970; p. 435.

    Google Scholar 

  46. Keen H., Jarrett R. J., Chlouverakis C., Boyns D. R.: The Effect of Treatment of Moderate Hyperglycaemia on the Incidence of Arterial Disease — Postgrad. med. J.44, 960, 1968.

    Article  Google Scholar 

  47. Keen H., Rose G. A., Pyke D. A., Boyns D. R., Chlouverakis C., Mistry S.: Blood Sugar and Arterial Disease — Lancet2, 505, 1965.

    Article  PubMed  CAS  Google Scholar 

  48. Krause U.: Tolbutamid und Myocardinfarkt — Pharm. Ztg (Frankfurt)15, 523, 1971.

    Google Scholar 

  49. Labeling of Oral Hypoglycemic Drugs — Diabetes21, 833, 1972.

  50. Loubatières A.: Therapeutic Aspects of Diabetes. Remarks Concerning Some Recent Reports on Therapy of Diabetes — In:Shafrir E. (Ed.): Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med. Sci.8, 883, 1972.

    Google Scholar 

  51. Lubetzki J.: Réflexions sur l’angiopathie diabétique. Rélations avec les traitements hypoglycémiants — Nouv. Presse méd.1, 715, 1972.

    PubMed  CAS  Google Scholar 

  52. Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus — Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 1971.

  53. Mahler R.: The Effect of Diabetes and Insulin on Biochemical Reactions of the Arterial Wall — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 68, 1971.

    Google Scholar 

  54. Mayne E. E., Bridges J. M., Weaver J. A.: Platelet Adhesiveness, Plasma Fibrinogen and Factor VIII Levels in Diabetes Mellitus — Diabetologia6, 436, 1970.

    Article  PubMed  CAS  Google Scholar 

  55. Miller M.: Factors Influencing the Progress of Atherosclerosis in the Diabetic — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 434, 1971.

    Google Scholar 

  56. Ødegaard A. E., Skaalhegg B. A., Hellem A. J.: Increased Activity of ‘Anti-Willebrand’ Factor in Diabetic Plasma — Thrombos. Diathes. haemorrh. (Stuttg.)11, 27, 1964.

    Google Scholar 

  57. Ostrander L. D. Jr., Francis T. Jr., Hayner N. S., Kjelsberg M. O., Epstein F. H.: The Relationship of Cardiovascular Disease to Hyperglycaemia — Ann. intern. Med.62, 1188, 1965.

    PubMed  Google Scholar 

  58. Paasikivi J.: Long-Term Tolbutamide Treatment after Myocardial Infarction. A Clinical and Biochemical Study of 178 Patients without Overt Diabetes — Acta med. scand.507 (Suppl.), 1, 1970.

    CAS  Google Scholar 

  59. Paasikivi J.: Long-Term Tolbutamide Treatment of Survivors from Myocardial Infarction — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet lat.8 (Suppl. 1), 437, 1971.

    Google Scholar 

  60. Paasikivi J., Wahlberg F.: Preventive Tolbutamide Treatment and Arterial Disease in Mild Hyperglycaemia — Diabetologia7, 323, 1971.

    Article  PubMed  CAS  Google Scholar 

  61. Pfeiffer E. F.: Factors Influencing the Epidemiology of and Interrelations between Atherosclerosis and Diabetes Mellitus — In:Lundbæk K., Keen H. (Eds): Blood Vessel Disease in Diabetes Mellitus. Casa Ed. «Il Ponte», Milano, 1971; Acta diabet. lat.8 (Suppl. 1), 425, 1971.

    Google Scholar 

  62. Pirart J.: L’affaire de l’University Group Diabetes Program (U.G.D.P.). Quelques réflexions personnelles. La tolbutamide et la phenformine au banc des accusés — Nouv. Presse méd.1, 325, 1972.

    PubMed  CAS  Google Scholar 

  63. Raheja B. S.: Hypoglycemic Agents and Cardiovascular Heart Disease in Diabetes — In:Shafrir E.: Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med. Sci.8, 701, 1972.

    Google Scholar 

  64. Ricketts H. T.: Editorial Statement — Diabetes19 (Suppl. 2), iii, 1970.

    Google Scholar 

  65. Schöffling K.: Indikationen und Nebenwirkungen der oralen Diabetestherapie — 6. Kongr. d. Dtsch. Diabetes Ges., Düsseldorf 1971. Quoted by:Müller R.: Lesioni vascolari da tolbutamide — Acta diabet. lat.8, 1219, 1971.

    Google Scholar 

  66. Schor S.: The University Group Diabetes Program. A Statistician Looks at the Mortality Results — J. Amer. med. Ass.217, 1673, 1971.

    Google Scholar 

  67. Seltzer H. S.: Tolbutamide Mortality in the Six ‘Phenformin Clinics’ — J. Amer. med. Ass.218, 594, 1971.

    Article  CAS  Google Scholar 

  68. Seltzer H. S.: A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (U.G.D.P.) — Diabetes21, 976, 1972.

    PubMed  CAS  Google Scholar 

  69. Shaper A. G., Lee K. T., Scott R. F., Goodale F., Thomas W. A.: Comparison of Adipose Tissue Fatty Acids and Plasma Lipids in Diabetics from East Africa and the United States with Different Frequencies of Myocardial Infarction — Amer. J. Cardiol.10, 390, 1962.

    Article  PubMed  CAS  Google Scholar 

  70. Statement on Treatment of Diabetes — Diabetes19, 527, 1970.

  71. Statement Regarding the University Group Diabetes Program (UGDP) Study. AMA Council on Drugs — Diabetes19 (Suppl. 2), vi, 1970.

    Google Scholar 

  72. Stout R. W.: Insulin-Stimulated Lipogenesis in Arterial Tissue in Relation to Diabetes and Atheroma — Lancet2, 702, 1968.

    Article  PubMed  CAS  Google Scholar 

  73. Teuscher A.: Sind orale Antidiabetika unwirksam — oder gar gefährlich? Das ‘University Group Diabetes Program’ (U.G.D.P.) als Ausgangspunkt einer Kontroverse über die Therapie des Altersdiabetes — Schweiz. med. Wschr.102, 848, 1972.

    PubMed  CAS  Google Scholar 

  74. Teuscher A.: Sind orale Antidiabetika unwirksam — oder gar gefährlich? — Tägl. Prax.14, 177, 1973.

    Google Scholar 

  75. Tzagournis M., Reynertson R.: Mortality from Coronary Heart Disease during Phenformin Therapy — Ann. intern. Med.76, 587, 1972.

    PubMed  CAS  Google Scholar 

  76. University Group Diabetes Program: A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients with Adult-Onset Diabetes. Part I: Design, Methods and Baseline Results — Diabetes19 (Suppl. 2), 747, 1970.

    Google Scholar 

  77. University Group Diabetes Program: A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients with Adult-Onset Diabetes. Part II: Mortality Results — Diabetes19 (Suppl. 2), 789, 1970.

    Google Scholar 

  78. University Group Diabetes Program: Effects of Hypoglycemic Agents on Vascular Complications in Patients with Adult-Onset Diabetes. IV. A Preliminary Report on Phenformin Results — J. Amer. med. Ass.217, 777, 1971.

    Article  Google Scholar 

  79. Weekley J. H.: Diabetologists Score FDA Action — Intern. Med. Diag. News3, no. 24, 1, 1970.

    Google Scholar 

  80. Weisenfeld S.: Discussion Remark. Panel Discussion on: Oral Substitutes for Insulin: Modern Appraisal of Their Action and Indications — In:Shafrir E. (Ed.): Impact of Insulin on Metabolic Pathways. International Symposium Commemorating the 50th Anniversary of Insulin. Jerusalem 1971; Israel J. med. Sci.8, 708, 1972.

    Google Scholar 

  81. Welborn T. A., Cumpston G. N., Cullen K. J., Curnow D. H., McCall M. G., Stenhouse N. S.: The Prevalence of Coronary Heart Disease and Associated Factors in an Australian Rural Community — Amer. J. Epidem.89, 521, 1969.

    CAS  Google Scholar 

  82. Wellmann K. F., Lazarus S. S., Volk B. W.: The Viscera in Sulfonylurea-Treated Diabetics — Metabolism12, 959, 1963.

    Google Scholar 

  83. World Health Organization: Epidemiological and Vital Statistic Report — World Health Organization, Genève, 1969.

    Google Scholar 

Download references

Authors
  1. Sergio Marigo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marigo, S. Misunderstanding or error?. Acta diabet. lat 11, CO1–422 (1974). https://doi.org/10.1007/BF02624579

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02624579

Keywords

Search

Navigation